Objective There is no consensus on the biochemical diagnostic criteria for subclinical hypercortisolism (SH). Using parameters related to the hypothalamic-pituitary-adrenal axis, we aimed to develop a diagnostic model of SH for predicting postsurgical hypocortisolism and metabolic complications. Design Prospective and cross-sectional, observational, multicentre study in Korea. Methods After exclusion of overt Cushing's syndrome, adrenal incidentaloma (AI) patients who underwent unilateral adrenalectomy (n = 99) and AI patients (n = 843) were included. Primary outcome was defined as the presence of postsurgical hypocortisolism; secondary outcome was the presence of ≥4 complications (components of the metabolic syndrome and low bone mass). Postsurgical hypocortisolism was determined on the fifth postsurgery day using the ACTH stimulation test. Results Thirty-three of the 99 patients developed postsurgical hypocortisolism. Analysis of the presurgery overnight 1-mg dexamethasone suppression test (1-mg DST) showed that all patients with cortisol levels of >138 nmol/l experienced postsurgical hypocortisolism, whereas those with levels of ≤61 nmol/l did not. The models of (i) 1-mg DST >138 nmol/l or (ii) >61 nmol/l with the presence of one among low levels of ACTH and dehydroepiandrosterone-sulphate had the highest accuracy (89Á9%, P < 0Á001) and odds ratio [OR 111Á62, 95% confidence interval (CI) 21Á98-566Á74, P < 0Á001] for predicting postsurgical hypocortisolism. Finally, patients with the same criteria in the 843 AI patients showed the highest risk for having ≥4 complications (OR 3Á51, 95% CI 1Á84-6Á69, P < 0Á001), regardless of gender, age, body mass index and bilaterality. Conclusions Our proposed model is able to accurately predict subtle cortisol excess and its chronic manifestations in AI patients.
Introduction
Subclinical hypercortisolism (SH) is defined as a condition with excessive biochemical cortisol levels without classical signs or symptoms of overt hypercortisolism, for example purple striae, easy bruising, proximal muscle weakness and plethora. 1, 2 Although emerging evidence suggests that SH should be corrected to prevent chronic sequelae, [3] [4] [5] [6] [7] [8] there is no consensus regarding the biochemical criteria for diagnosing SH. 1 At present, SH diagnosis relies on altered biochemical parameters related to the hypothalamic-pituitary-adrenal (HPA) axis with different cut-off levels, for example (i) lack of cortisol suppression after a 1-mg overnight dexamethasone suppression test (1-mg DST); (ii) elevated 24-h urinary-free cortisol (UFC) levels; (iii) loss of cortisol diurnal rhythm; (iv) low ACTH levels; and/or (v) low dehydroepiandrosterone-sulphate (DHEA-S) levels. 1, 2, [9] [10] [11] [12] [13] [14] [15] The absence of gold standard criteria, mainly originating from a lack of large-scale prospective studies regarding its long-term sequelae, 1, 6, 14, 16 makes it challenging for clinicians to diagnose SH. The chronic sequelae of SH, for example metabolic syndrome (MetS) components and low bone mass, occur more frequently even in healthy adults, 17 compared with the occurrence of SH (prevalence 0Á2-2Á0%).
1
A large-scale, long-term prospective study to demonstrate a statistically clear cut-off point has therefore proven difficult to perform. In this context, a recommendation for adrenalectomy in patients with SH largely depends on expert opinion. 1, 2, [9] [10] [11] [12] 14, 15 In our study, we hypothesized that the occurrence of immediate, postsurgical hypocortisolism might provide an alternative standard for diagnosing SH, because it indicates a presurgical inappropriate cortisol elevation. 1, 18 However, only one study has previously evaluated the diagnostic criteria of SH using postsurgical hypocortisolism occurrence. 18 In that study, the presence of >2 alterations among 1-mg DST > 138 nmol/l, ACTH <2Á2 pmol/l, elevated UFC and midnight serum cortisol had the highest odds ratio (OR) for predicting postsurgical hypocortisolism [OR 10Á45, 95% confidence interval (CI) 2Á54-42Á95]. However, that study suggested that postsurgical hypocortisolism could not completely be ruled out due to the <71Á7% accuracy of any parameter combinations; in addition, the clinical relevance of the diagnostic criteria was not evaluated. In our multi-centre, prospective study on a relatively larger number of patients, we developed diagnostic criteria with improved prediction (OR 111Á62, 95% CI 21Á98-566Á74) and accuracy (89Á9%) for SH. Furthermore, we confirmed that the same diagnostic criteria were associated with metabolic complications in a large-scale, cross-sectional design.
Subjects and methods

Ethics statement
All participants provided written informed consent. All studies were approved by the Ethics Review Committees of the respective institutions.
Study population of the postsurgical hypocortisolism set
This study population was based on the 'Co-work Of Adrenal Research (COAR)' study (clinicaltrial.gov No. NCT01382420), which was a randomized, parallel-group, multicentre, openlabelled trial conducted at Asan Medical Center, Samsung Medical Center and Konkuk University Medical Center in Korea. From July 2011 to June 2014, we recruited 1059 consecutive, newly diagnosed patients with adrenal incidentaloma (AI). AI diagnosis was based on the detection of an adrenal mass (≥1 cm) via computed tomography, which was performed for an unrelated disease. In all patients, we measured the levels of basal morning (09:00 h) ACTH and cortisol, UFC, 1-mg DST (09:00 h), DHEA-S, 24-h urinary fractionated metanephrines, plasma aldosterone and plasma renin activity at baseline. Among 1059 patients, we excluded 95 and classified the remaining 964 patients by endocrine evaluation (detailed in Fig. 1 ). A total of 46 of 164 patients who were suspected to have SH by at least 2 lack of suppression in 1-mg DST with a cutoff value of 50 nmol/L, 13 consented to and underwent adrenalectomy. 'would change to 'A total of 46 of 164 patients who were suspected to have SH by lack of suppression in the mean value of 1-mg DST with a cut-off value of 50 nmol-L, 13 consented to and underwent adrenalectomy. Considering that adrenal failure occurs more frequently in the presence of stressful events, prophylactic steroid therapy was administered immediately before surgery until the third postoperative day in all patients who were suspected to have SH. On the fifth postoperative day, without hydrocortisone replacement for 1 day, postsurgical hypocortisolism was assessed using a standard ACTH stimulation test. A peak serum cortisol level of <497 nmol/l was considered as postsurgical hypocortisolism. 19 We evaluated the occurrence of postsurgical hypocortisolism in 99 patients; all 46 patients who were suspected to have SH, 19 of 38 patients who had primary aldosteronism due to adenoma, 23 of 54 patients who had phaeochromocytoma and 11 of 54 patients who had nonfunctional AI (detailed in Fig. 1 ). Patients who were not suspected to have SH were randomly chosen by their clinicians for the evaluation of postsurgical hypocortisolism. Prior to the ACTH stimulation test, patients with possible acute illness or stressful condition were excluded by an expert endocrinologist.
Study population of the metabolic complication set
We evaluated the association of SH with metabolic complications, such as components of the MetS and low bone mass, in all study patients. The components of the MetS were defined according to the 2005 revised criteria of the National Cholesterol Education Program Adult Treatment Panel III, which included (i) abdominal obesity (waist circumference of ≥90 cm for men and ≥85 cm for women based on an Asian-specific cut-off point); (ii) hypertriglyceridaemia (≥1Á7 mmol/l); (iii) low high-density lipoprotein cholesterol (<1Á0 mmol/l for men and <1Á3 mmol/l for women); (iv) high blood pressure (≥130/ 85 mmHg) or use of an antihypertensive medication and (v) high fasting plasma glucose (≥5Á6 mmol/l) or use of antidiabetic medication (e.g. insulin or oral agents). 20 Low bone mass was defined as 'low bone mineral density (BMD) for chronological age' in premenopausal women and men of <50 years of age when Z-score was ≤À2Á0 and as 'osteoporosis' in postmenopausal women and men of ≥50 years of age when T-score was ≤À2Á5 21 or when the use of anti-osteoporotic medications was involved, for example bisphosphonate or oestrogen therapy. Among 964 patients, 121 (60 with probable phaeochromocytoma and 61 with probable primary aldosteronism) were excluded because their conditions are known to affect blood pressure and/or the metabolism of glucose and lipids.
Methods for measurement of anthropometric, hormonal, biochemical and BMD data All measurements of anthropometric, hormonal, biochemical and BMD data were performed at each of the three medical centres. We performed the 1-mg DST twice and used the mean value for analysis in those with a value of >50 nmol/l. Differences in serum cortisol assays among the centres were monitored on a quarterly basis by an external quality control programme of the Korean Society of Nuclear Medicine using standard specimens with low, middle and high cortisol levels (http://qc.ksnmt.or.kr/ria). All the centres satisfied the criteria for comparability with an absolute value of Z-score of <2.
Statistical analysis
Statistical analysis was performed by SPSS version 12Á0 (SPSS Inc., Chicago, IL, USA). The results are expressed as mean AE standard deviation, unless otherwise specified. P < 0Á05 was considered to indicate statistical significance.
In the postsurgical hypocortisolism set, comparison of continuous and categorical variables between groups defined by postsurgical hypocortisolism status was performed using Student's t-test and chi-square test, respectively. The ability of the 1-mg DST to predict postsurgical hypocortisolism was quantified using the area under the receiver operating characteristic (ROC) curve (AUC). We calculated specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of the presurgical parameters of the HPA axis for predicting postsurgical hypocortisolism. Logistic regression analysis was used to assess the association between the presence of postsurgical hypocortisolism and models using single or a combination of the presurgical parameters of the HPA axis.
In the metabolic complication set, data of the groups according to the number of metabolic complications were compared using one-way analysis of variance for continuous variables and chi-square test for categorical variables. We calculated specificity, sensitivity, PPV, NPV and accuracy of models using the presurgical parameters of the HPA axis for predicting the occurrence of ≥4 metabolic complications. Logistic regression analysis was used to assess the association between the presence of ≥4 metabolic complications and models using the presurgical parameters of the HPA axis.
Results
Postsurgical hypocortisolism set Table 1 shows the clinical characteristics according to the occurrence (n = 33) or absence (n = 66) of postsurgical This study suggests that the diagnostic model for subclinical hypercortisolism (SH) be performed in two parts. First, we determined the diagnostic models for predicting the presence of postsurgical hypocortisolism in 99 patients based on parameters of the hypothalamic-pituitary-adrenal (HPA) axis (the postsurgical hypocortisolism set). Second, we replicated these models to predict the presence of metabolic complications, such as any one of the components of metabolic syndrome and low bone mass, in 843 patients with adrenal incidentaloma (AI) (the metabolic complication set).
hypocortisolism. Age, body mass index (BMI), adenoma diameter and bilaterality did not differ between the groups. Among the HPA axis parameters, the levels of ACTH, DHEA-S and 1-mg DST differed between the groups, whereas UFC and morning cortisol levels were comparable. Figure 2a shows the individual data of presurgical 1-mg DST according to postsurgical hypocortisolism status. All patients with 1-mg DST >138 nmol/l experienced postsurgical hypocortisolism, whereas those with 1-mg DST ≤61 nmol/l did not experience it. Some patients with 1-mg DST between 61 and 138 nmol/l experienced postsurgical hypocortisolism; therefore, other parameters were needed to improve the prediction of postsurgical hypocortisolism. In the ROC curve of 1-mg DST (AUC = 0Á965) (Fig. 2b) , the best cutoff value, which corresponded to Youden's index, 22 was 61 nmol/l; the second cut-off value was 83 nmol/l. There was a significant difference in the AUC between the mean values and first measured values of the 1-mg DST (0Á965 vs 0Á948, P = 0Á049). We made 13 models using single or a combination of the following parameters of the HPA axis: 1-mg DST, low ACTH level (<2Á2 pmol/l) and low DHEA-S level (lower level of normal range is <2Á17 lmol/l in males or <0Á95 lmol/l in females).
1 UFC was excluded in these models because of its well-known high variability 1, 23 and the similarity of UFC values between patients with and without postsurgical hypocortisolism (Table 1) . Table 2 reports the sensitivity, specificity, PPV, NPV and accuracy of these models for predicting postsurgical hypocortisolism. Six models (I, II, VII, VIII, XI and XII) had an accuracy of >85% with statistical significance (P < 0Á05); model VIII (1-mg DST >138 nmol/l or 1-mg DST >61 nmol/l in the presence of low levels of ACTH or DHEA-S) had the highest accuracy (89Á9%, P < 0Á001). The AUC of models that included DHEA-S (models VIII and XII) was significantly higher than those that excluded DHEA-S (models VI and X) (0Á886 for model VIII vs 0Á788 for model VI, P = 0Á014; 0Á848 for model XII vs 0Á773 for model X, P = 0Á034). After adjustment for potential confounders, model VIII remained as the one with the highest association with postsurgical hypocortisolism (OR 111Á62, 95% CI 21Á98-566Á74, P < 0Á001) ( Table 2) . No other confounder (age, BMI, adenoma diameter and bilaterality) was significant. After excluding patients with phaeochromocytoma and primary aldosteronism, model VIII had the highest accuracy (83Á6%, P < 0Á001) and highest OR (51Á96, 95% CI 7Á18-375Á90) among all other models (data not shown).
Metabolic complication set
With an increase in the number of metabolic complications (five components of MetS and low bone mass), the 1-mg DST value showed a tendency to increase, for example 41 AE 28 nmol/l in patients with zero complications, 41 AE 28 nmol/l in those with one complication, 50 AE 41 nmol/l in those with two complications, 50 AE 41 nmol/l in those with three complications and 64 AE 52 nmol/l in those with ≥4 complications (test for linear tendency among means: F = 5Á673, P < 0Á001). The other hormonal parameters were not associated with the number of metabolic complications. The difference in 1-mg DST value was only significant between patients with zero complications and patients with ≥4 complications (P = 0Á006). Hence, we compared the clinical characteristics according to the presence (n = 107) or absence (n = 736) of ≥4 metabolic complications. Compared with patients with ≤3 metabolic complications, those with ≥4 metabolic complications showed higher 1-mg DST (64 AE 52 nmol/l vs 47 AE 36 nmol/l, P < 0Á001) and lower DHEA-S (1Á87 AE 1Á36 lmol/l vs 2Á33 AE 1Á65 lmol/l, P = 0Á022) ( Table 3) . No difference in ACTH and UFC levels and adenoma diameter was found. Table 4 reports the sensitivity, specificity, PPV, NPV and accuracy of the 13 models for predicting the occurrence of ≥4 metabolic complications. Only two models (VII and VIII) had significantly higher accuracy of ≥85% (P < 0Á05). After adjustment for confounders, model VIII displayed the strongest association with the presence of ≥4 metabolic complications (OR 3Á51, 95% CI 1Á84-6Á69) (P < 0Á001) (Table 4) , consistent with the diagnostic criteria for predicting postsurgical hypocortisolism shown in Table 2 . After excluding low bone mass, only model VIII had a significantly high accuracy of ≥85% (P = 0Á038) and showed the highest OR (3Á20, 95% CI 1Á60-6Á38) (data not shown).
Discussion
Here, we showed that one model, that is model VIII [the presence of 1-mg DST >138 nmol/l or 1-mg DST >61 nmol/l with Fig. 2 (a) Individual data on cortisol levels after the 1-mg dexamethasone suppression test (1-mg DST), according to the development of postsurgical hypocortisolism, (b) receiver operating characteristic curve for the prediction of postsurgical hypocortisolism, based on cortisol levels after 1-mg DST. Table 2 . Diagnostic accuracy of the 13 models using either single or a combination of the parameters of the hypothalamic-pituitary-adrenal axis, and odds ratio of six models with accuracy of ≥85% and P < 0Á05 for predicting the presence of postsurgical hypocortisolism
Model Parameters
Diagnostic accuracy Sensitivity Specificity PPV NPV Accuracy P
Model (presence/absence) OR* 95% CI P Model I: A 4Á98 9 10
Data are expressed as percentages. A, 1-mg DST > 61 nmol/l (2Á2 lg/dl); B, 1-mg DST > 83 nmol/l (3Á0 lg/dl); C = 1-mg DST > 138 nmol/l (5Á0 lg/dl); D, low ACTH level <2Á2 pmol/l (10 pg/ml); E, low DHEA-S level [<2Á17 lmol/l (80 lg/dl) in males or <0Á95 lmol/l (35 lg/dl) in females]; DHEA-S, dehydroepiandrosterone-sulphate; NA, not applicable; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; 1-mg DST, cortisol level after an overnight 1-mg dexamethasone suppression test; CI = confidence interval. The models with accuracy of ≥85% and P < 0Á05 are in bold. *OR: adjusted for gender (female), age (1-year increase), body mass index (1-kg/m 2 increase), diameter of adenoma (1-cm increase) and site (bilateral lesion).
the presence of one parameter among low levels of ACTH and DHEA-S] may be the best model for diagnosing SH. Model VIII predicted postsurgical hypocortisolism with an accuracy of 89Á9%. From the perspective of clinical effectiveness, model VIII also had the strongest association with metabolic complications.
To the best of our knowledge, ours is the first study to report a model for SH diagnosis with both accuracy and clinical effectiveness.
To date, the definition of SH has been widely accepted, although the biochemical criteria for diagnosing SH still remain controversial. 1 Because of the low reliability of hormonal assays (e.g. UFC and ACTH levels), fluctuation of cortisol secretion and lack of a gold standard diagnostic tool, SH diagnosis has often been difficult. 1,2,9-15 Despite these difficulties, SH has been shown to be associated with several metabolic complications, such as insulin resistance, hypertension, hyperglycaemia, obesity and dyslipidaemia; increased risk for osteoporosis, vertebral fractures and cardiovascular events; and mortality. [3] [4] [5] [6] [7] [8] We also observed that the 1-mg DST increased along with an increase in the number of metabolic complications. Therefore, adrenalectomy seems to be beneficial for SH patients; 16, [24] [25] [26] the best diagnostic approach for identifying SH patients who may benefit from surgery is needed. To discover models for diagnosing SH, we investigated the association between several HPA axis parameters and postsurgical hypocortisolism as the gold standard for diagnosing SH. 1, 18 Although the suggested cut-off is still debated among 50, 83 and 138 nmol/l, the 1-mg DST is the most widely used and sensitive screening test.
1,2,9-15 Therefore, we used 1 mg as our dose of dexamethasone (and not 1Á5 mg, 2 mg or a weight-related dose) and initially investigated the accuracy of the 1-mg DST. All patients with a 1-mg DST >138 nmol/l experienced postsurgical hypocortisolism. Despite good specificity, applying a cut-off of 138 nmol/l could miss some SH patients because of low sensitivity. No patients with 1-mg DST ≤61 nmol/l, higher than the suggested cut-off of 50 nmol/l, 13 experienced postsurgical hypocortisolism. However, not all patients with a 1-mg DST value between 61 and 138 nmol/l experienced postsurgical hypocortisolism. Therefore, we discovered that the 13 models, which combined 1-mg DST with other parameters, improved predictability; in particular, model VIII had the highest accuracy for predicting postsurgical hypocortisolism. We also investigated the association between the 13 models and metabolic complications as the other gold standard for diagnosing SH. 1, 17 Consistently, model VIII had the highest accuracy for predicting metabolic complications. This suggested that model VIII provides the best diagnostic criteria for SH and that the occurrence of postsurgical hypocortisolism may be a useful gold standard for diagnosing SH. The other 1-mg DST cut-off of 83 nmol/l, which has been suggested by some studies, 1, 17, 18, 25 had good accuracy, either alone (87Á9% in model II) or in combination with other parameters (87Á9% in model XII), for predicting postsurgical hypocortisolism. However, these models were not significantly associated with the occurrence of metabolic complications. Therefore, we suggest 61 nmol/l, rather than 83 nmol/l, as the 1-mg DST cut-off value that should be applied in practice. The absence of an association between the presence of metabolic complications and four of the six models with high accuracy for predicting postsurgical hypocortisolism might be surprising. If postsurgical hypocortisolism is considered a reliable index of SH, it would be expected that the development of metabolic complications could also be predicted by all models for predicting postsurgical hypocortisolism. However, metabolic complications are frequently observed regardless of SH presence. Furthermore, because of the duration, extent and timing of cortisol imbalance and the various glucocorticoid sensitivities between individuals, and in different tissues in the same individual, 27 subtle hypercortisolaemia in some patients might suffice for suppressing the HPA axis, but not for deleterious effects on the end-organ.
In our study, model VIII showed higher accuracy (89Á9%) and OR (111Á62, 95% CI 21Á98-566Á74) for predicting postsurgical hypocortisolism, compared with that of a previous study, which used a similar approach to ours (accuracy <71Á7%, OR 10Á45, 95% CI 2Á54-42Á95). 18 There are several differences between that study and this one. First, we did not measure Table 3 . Clinical features of patients with adrenal incidentaloma, according to the development of ≥4 metabolic complications (five components of the metabolic syndrome and low bone mass*)
47 AE 36 64 AE 52 <0Á001
BMI, body mass index; DHEA-S, dehydroepiandrosterone-sulphate; HU, Hounsfield unit; UFC, urine-free cortisol; 1-mg DST, cortisol level after an overnight 1-mg dexamethasone suppression test. Significant results (P < 0Á05) are in bold. *Low bone mass was defined as 'low bone mineral density for chronological age' in premenopausal women and men of <50 years of age when Z-score was ≤À2Á0 and as 'osteoporosis' in postmenopausal women and men of ≥50 years of age when T-score was ≤À2Á5 or when the use of anti-osteoporotic medications was involved, for example bisphosphonate or oestrogen therapy.
midnight serum cortisol because we intended to determine the diagnostic criteria without the need for hospitalization. Therefore, adding the midnight serum cortisol level might improve accuracy. Second, we measured 1-mg DST twice, whereas EllerVainicher et al. did the measurement at least once. The mean values had higher accuracy than a single-measured value; therefore, 1-mg DST should be repeated in patients with levels of >50 nmol/l to improve accuracy and minimize false positivity. Third, we used a standard, high-dose (250 lg) ACTH stimulation test, whereas they used the low-dose (1 lg) ACTH stimulation test for determining postsurgical hypocortisolism. The low-dose test might be more sensitive than the high-dose test for diagnosing hypocortisolism. 28 However, there are conflicting reports on the diagnostic value using the low-dose test compared with high-dose test; 29, 30 one report in Korea found a higher ROC curve for diagnosing hypocortisolism with the high-dose test than with the low-dose test. 31 We thus used the high-dose ACTH stimulation test in our study. Fourth, we assessed postsurgical hypocortisolism immediately, whereas they assessed this 2 months postsurgery. Because of the possibility of spontaneous resolution within 2 months, postsurgical hypocortisolism should be immediately evaluated postsurgery if stressful conditions can be excluded. Fifth, the previous study had lower statistical power because of the relatively smaller number of patients without postsurgical hypocortisolism, mainly due to the exclusion of patients with primary aldosteronism and phaeochromocytoma.
In contrast, our model retained high accuracy even after excluding such patients. Sixth, we used DHEA-S, but not UFC, because there were no differences in UFC according to postsurgical hypocortisolism status. Consistent with our findings, it has been reported that UFC cannot reliably reveal slight cortisol excess 1, 23 and may have technical problems in measurement.
1,23,32 Table 4 . Diagnostic accuracy of the 13 models using either single or a combination of the parameters of the hypothalamic-pituitary-adrenal axis, and odds ratio of six models with accuracy of ≥85% and P < 0Á05 for predicting the presence of ≥4 metabolic complications of SH (five components of the metabolic syndrome and low bone mass*)
Model Criteria
Data are expressed as percentages. A, 1-mg DST > 61 nmol/l (2Á2 lg/dl); B, 1-mg DST > 83 nmol/l (3Á0 lg/dl); C, 1-mg DST > 138 nmol/l (5Á0 lg/dl); D, low ACTH level <2Á2 pmol/l (10 pg/ml); E, low DHEA-S level [<2Á17 lmol/l (80 lg/dl) in males or <0Á95 lmol/l (35 lg/dl) in females]; BMI, body mass index; DHEA-S, dehydroepiandrosterone-sulphate; NPV, negative predictive value; PPV, positive predictive value; 1-mg DST, cortisol level after an overnight 1-mg dexamethasone suppression test. The models with accuracy of ≥85% and P < 0Á05 are in bold. *Low bone mass was defined as 'low bone mineral density for chronological age' in premenopausal women and men of <50 years of age when Z-score was ≤À2Á0 and as 'osteoporosis' in postmenopausal women and men of ≥50 years of age when T-score was ≤À2Á5 or when the use of anti-osteoporotic medications was involved, for example bisphosphonate or oestrogen therapy. †OR: adjusted for gender (female), age (1-year increase), BMI (1-kg/m 2 increase), diameter of adenoma (1-cm increase) and site (bilateral lesion).
Therefore, UFC should not be considered as an adequate screening test for SH. 1,2 Excluding UFC may have increased the accuracy of our results. Although the reliability of DHEA-S as a marker of SH is debatable, 1 inclusion of DHEA-S increased the accuracy. Thus, we propose that DHEA-S should only be used in combination with the 1-mg DST. Lastly, they did not investigate the association of their criteria with the development of metabolic complications; in contrast, we showed a significant association of our models with metabolic complications in this large-scale, cross-sectional design. Our study had several limitations. First, the inadequacies of current dynamic steroid testing protocols, such as the ACTH stimulation test and DST, still apply. Second, the metabolic complication set was investigated via a cross-sectional observational design; therefore, it can show association, but does not prove causality. Third, SH may be present even in patients without postsurgical hypocortisolism because of the deleterious effect of slight hypercortisolaemia on some tissues even before the HPA axis is overtly suppressed. Even though we present model VIII as the best proposed SH diagnostic test, conducting a longitudinal observational study or a large prospective randomized study on the changes in metabolic complications after conservative or surgical treatment would still be important in identifying the best SH diagnostic criteria for predicting the usefulness of surgery. Fourth, our results may not necessarily be generalizable as we undertook our study in a Korean population. Finally, we have not attempted to replicate our results in other independent cohorts.
In summary, a suggested diagnostic model for SH based on our analysis, specifically 1-mg DST >138 nmol/l or >61 nmol/l in the presence of low levels of ACTH or DHEA-S, seems to be the best criterion for predicting subtle cortisol excess and its chronic manifestations.
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